Short-Term Inhibition of Parathyroid Hormone Secretion by a Calcium-Receptor Agonist in Patients with Primary Hyperparathyroidism
Open Access
- 20 November 1997
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 337 (21), 1506-1511
- https://doi.org/10.1056/nejm199711203372104
Abstract
Surgery is the usual therapy for patients with primary hyperparathyroidism. We investigated the ability of a calcimimetic drug that inhibits parathyroid hormone secretion in vitro to decrease serum parathyroid hormone and calcium concentrations in patients with this disorder.Keywords
This publication has 21 references indexed in Scilit:
- Evaluation and management of primary hyperparathyroidismJournal of Clinical Endocrinology & Metabolism, 1996
- Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidismJournal of Clinical Endocrinology & Metabolism, 1995
- Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroidNature, 1993
- Journal of Bone and Mineral ResearchJournal of Bone and Mineral Research, 1991
- Journal of Bone and Mineral ResearchJournal of Bone and Mineral Research, 1991
- Improved vertebral fracture threshold in postmenopausal osteoporosis by radiogrametric measurements: Its usefulness in selection for preventive therapyJournal of Bone and Mineral Research, 1991
- Ethinyl Estradiol and Norethindrone in the Treatment of Primary Hyperparathyroidism in Postmenopausal WomenNew England Journal of Medicine, 1986
- Treatment of hyperparathyroidism with etidronate disodiumPublished by American Medical Association (AMA) ,1983
- Drug treatment of primary hyperparathyroidism: use of clodronate disodium.BMJ, 1983
- STUDIES IN PARATHYROID PHYSIOLOGYJCI Insight, 1932